Selecta Biosciences (SELB) Misses Q4 EPS by 7c

Selecta Biosciences (NASDAQ: SELB) reported Q4 EPS of ($0.28), $0.07 worse than the analyst estimate of ($0.21).

“2019 was a pivotal year for Selecta. We made substantial clinical advancements, as we completed enrollment in the head-to-head COMPARE trial for our lead product candidate, SEL-212, in chronic refractory gout, and advanced our gene therapy program through strategic partnerships with AskBio. We also strengthened our organization with the addition of several key members to the executive team and welcomed a new Chairman of our Board of Directors, and completed a $70 million financing,” said Carsten Brunn, Ph.D., President and CEO of Selecta. “In the coming year, we look forward to reporting topline data from the COMPARE study, commencing the Phase 3 clinical program of SEL-212, and advancing our gene therapy program into the clinic in partnership with AskBio.”

For earnings history and earnings-related data on Selecta Biosciences (SELB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Evogene chairman to address dissident shareholders on results call
• Movano (MOVE) Misses Q2 EPS by 195c